PI11343 (S)-2-(3-((2-Isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoic acid (CAS No.: 154212-61-0)

(S)-2-(3-((2-Isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoic acid (CAS No.: 154212-61-0) Description

This compound, with a molecular formula of C14H23N3O3S and CAS Number 154212-61-0, is provided in powder form. It is synthesised for use as an intermediate in pharmaceutical production. The documented synthetic pathway and analytical verification steps, including HPLC and NMR tests, facilitate its integration into process development where consistent reactivity and purity are essential.

(S)-2-(3-((2-Isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoic acid (CAS No.: 154212-61-0) Applications

1.       Pharmaceutical Synthesis
   - Used as a synthetic intermediate in active pharmaceutical ingredient production to streamline reaction sequences by leveraging its defined reactivity.
   - Applied in the development of drug candidates to expedite intermediary formation while ensuring high structural fidelity.

2.       Research & Process Development
   - Serves as a reference material in laboratory synthesis trials to achieve predictable chemical transformations by utilising its reproducible quality.
   - Employed in formulation studies to optimise reaction conditions, thereby reducing variability in pilot scale batches.

(S)-2-(3-((2-Isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoic acid (CAS No.: 154212-61-0) Packing

The compound is packaged in sealed, moisture-resistant containers with an inner lining to prevent contamination. The packaging includes an inert gas purge option to maintain chemical stability during storage and transportation. Instructions for storage in a cool, dry area are provided, and customisation such as batch labelling and tamper-evident seals can be arranged as specified.

Additional Information

Chemical intermediates such as this one play a critical role in pharmaceutical manufacturing, where precise molecular control is essential. The synthesis and processing protocols are developed using established chemical engineering principles, ensuring that each batch meets the stringent requirements for pharmaceutical development.

Understanding the interplay between synthesis pathways and analytical validation is crucial in the production of intermediates. This knowledge supports the advancement of new drugs by providing a reproducibly controlled material that fits within both laboratory research and industrial-scale processes.